Toward stratification of patients with pancreatic cancer: Past lessons from traditional approaches and future applications with physical biomarkers

Eugene J. Koay, Ahmed M. Amer, Flavio E. Baio, Alexander O. Ondari, Jason B. Fleming

Research output: Contribution to journalReview articlepeer-review

19 Scopus citations

Abstract

Pancreatic ductal adenocarcinoma (PDAC) has a high mortality rate and outcomes have not improved substantially for decades. Significant attention has focused on the biological drivers of the disease, and preclinical work has pointed to multiple biomarker candidates and therapeutic avenues. However, translation of these promising biomarkers and treatment strategies to patients has not been overwhelmingly successful. New strategies to account for the significant heterogeneity of the disease are needed so that rational treatments can be administered. Here, we focus on how physical sciences-based approaches may play a role in stratifying patients for clinical trials, and how this view of PDAC may reinvigorate treatment strategies that have been abandoned after “failing” to fulfill their potential in unselected patient populations. By complementing biological approaches, the development of physical biomarkers of PDAC may help deliver on the promise of personalized medicine for this devastating disease.

Original languageEnglish (US)
Pages (from-to)237-243
Number of pages7
JournalCancer Letters
Volume381
Issue number1
DOIs
StatePublished - Oct 10 2016

Keywords

  • Drug resistance
  • Mass transport
  • Oncophysics
  • Pancreatic cancer
  • Tumor microenvironment

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Toward stratification of patients with pancreatic cancer: Past lessons from traditional approaches and future applications with physical biomarkers'. Together they form a unique fingerprint.

Cite this